利妥昔单抗治疗原发性中枢神经系统血管炎：病例报告。
Treatment of primary CNS vasculitis with rituximab: case report.
机构信息
From Unità Operativa di Reumatologia (C.S.), Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico; IRCSS-Arcispedale Santa Maria Nuova (C.S.), Reggio Emilia, Italy; and Mayo Clinic (R.D.B., J.H., J.M.M., G.G.H.), Rochester, MN.
出版信息
Neurology. 2014 Apr 8;82(14):1287-8. doi: 10.1212/WNL.0000000000000293. Epub 2014 Mar 5.
Primary CNS vasculitis (PCNSV) is an uncommon disorder of unknown cause that is restricted to brain and spinal cord. Glucocorticoids alone or in combination with cyclophosphamide achieve a favorable response in most patients.(1,2) However, some patients are intolerant or respond poorly to cyclophosphamide; therefore, there is the need for new treatment options. We report a patient with PCNSV who appeared to respond to treatment with corticosteroids and rituximab. This study was approved by the Mayo Clinic Institutional Review Board and written informed patient consent to perform the study was obtained.
原发性中枢神经系统血管炎（PCNSV）是一种少见的病因不明的疾病，仅局限于脑和脊髓。单独使用糖皮质激素或联合环磷酰胺治疗可使大多数患者获得良好的反应。(1,2) 然而，一些患者对环磷酰胺不耐受或反应不佳；因此，需要新的治疗选择。我们报告了一例 PCNSV 患者，该患者似乎对皮质类固醇和利妥昔单抗治疗有反应。该研究获得了 Mayo 诊所机构审查委员会的批准，并获得了患者书面知情同意进行该研究。
Zotero 插件